Compare FEIM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | TLSA |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 145.1M |
| IPO Year | 1994 | 2017 |
| Metric | FEIM | TLSA |
|---|---|---|
| Price | $85.14 | $1.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $95.50 | $7.99 |
| AVG Volume (30 Days) | 365.1K | ★ 599.2K |
| Earning Date | 09-10-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $63,227,000.00 | N/A |
| Revenue This Year | $30.80 | N/A |
| Revenue Next Year | $26.18 | N/A |
| P/E Ratio | $208.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.05 | $0.76 |
| 52 Week High | $89.76 | $2.33 |
| Indicator | FEIM | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 56.88 |
| Support Level | $48.49 | $0.90 |
| Resistance Level | $89.68 | $1.20 |
| Average True Range (ATR) | 4.17 | 0.10 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 53.24 | 79.00 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.